Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
The global Epirubicin Hydrochloride API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epirubicin Hydrochloride API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Epirubicin Hydrochloride API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epirubicin Hydrochloride API include Synbias-Gemini, TAPI, MicroBiopharm Japan, Olon S.p.A., Sterling Biotech, Lunan Pharmaceutical, Zhejiang Hisun and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epirubicin Hydrochloride API market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epirubicin Hydrochloride API Market by Company
- Synbias-Gemini
- TAPI
- MicroBiopharm Japan
- Olon S.p.A.
- Sterling Biotech
- Lunan Pharmaceutical
- Zhejiang Hisun
- DZD (Heze) Pharmaceutical
Epirubicin Hydrochloride API Segment by Type
- USP Grade
- EP Grade
- CP Grade
- JP Grade
- BP Grade
- Others
Epirubicin Hydrochloride API Segment by Application
- Injection
- Freeze-dried Powder Injection
Epirubicin Hydrochloride API Segment by Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Poland
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Türkiye
- GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epirubicin Hydrochloride API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Epirubicin Hydrochloride API and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market
- This report helps stakeholders to gain insights into which regions to target globally
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epirubicin Hydrochloride API.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epirubicin Hydrochloride API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epirubicin Hydrochloride API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epirubicin Hydrochloride API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
